Hemopure Study Set For Committee Review, Firm Says
This article was originally published in The Pink Sheet Daily
Biopure's oxygen therapeutic Hemopure [hemoglobin glutamer - 250 (bovine)] will be the topic of an FDA advisory committee July 14, the firm says
You may also be interested in...
The FDA committee would likely discuss circumstances under which the agency could lift a clinical hold that has been on the Hemopure trial since the IND was submitted in June 2005.
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
With an unrestricted label and once-daily dosing, rivaroxaban will do battle with Boehringer-Ingelheim's dabigatran, which is dosed twice a day but can claim superior efficacy to warfarin in the atrial fibrillation population.